Review





Similar Products

recombinant porcine upa  (Innovative Research Inc)
93
Innovative Research Inc recombinant porcine upa
Recombinant Porcine Upa, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant porcine upa/product/Innovative Research Inc
Average 93 stars, based on 1 article reviews
recombinant porcine upa - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
upa  (MedChemExpress)
94
MedChemExpress upa
<t>UPA</t> inhibits inflammation by silencing IFIT3 in <t>LPS-stimulated</t> <t>macrophages.</t> ( A ) mRNA levels of IFIT3, TNF-α, IL-1β and IL-6 in 100 ng/mL LPS-stimulated macrophages with untreated or treated with 100 nM and 400 nM UPA. ( B ) Protein levels of STAT1, pSTAT1, STAT2, pSTAT2 and IFIT3 among cell-groups. ( C ) Schematic diagram of relation among UPA, IFIT3 and STAT1/2 pathways. Data was presented as mean ± SD from 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Upa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/upa/product/MedChemExpress
Average 94 stars, based on 1 article reviews
upa - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
primary antibodies against plau  (Proteintech)
94
Proteintech primary antibodies against plau
In vitro experiments confirming ellagic acid (EA) target on <t>PLAU</t> to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Primary Antibodies Against Plau, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against plau/product/Proteintech
Average 94 stars, based on 1 article reviews
primary antibodies against plau - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
plau 17968 1 ap antibodies  (Proteintech)
94
Proteintech plau 17968 1 ap antibodies
In vitro experiments confirming ellagic acid (EA) target on <t>PLAU</t> to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Plau 17968 1 Ap Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plau 17968 1 ap antibodies/product/Proteintech
Average 94 stars, based on 1 article reviews
plau 17968 1 ap antibodies - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
urokinase type plasminogen activator upa  (Innovative Research Inc)
93
Innovative Research Inc urokinase type plasminogen activator upa
In vitro experiments confirming ellagic acid (EA) target on <t>PLAU</t> to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Urokinase Type Plasminogen Activator Upa, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/urokinase type plasminogen activator upa/product/Innovative Research Inc
Average 93 stars, based on 1 article reviews
urokinase type plasminogen activator upa - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
upa inhibitor  (MedChemExpress)
93
MedChemExpress upa inhibitor
In vitro experiments confirming ellagic acid (EA) target on <t>PLAU</t> to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Upa Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/upa inhibitor/product/MedChemExpress
Average 93 stars, based on 1 article reviews
upa inhibitor - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
upa  (TargetMol)
94
TargetMol upa
In vitro experiments confirming ellagic acid (EA) target on <t>PLAU</t> to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Upa, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/upa/product/TargetMol
Average 94 stars, based on 1 article reviews
upa - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
urokinase type plasminogen activator upa  (MedChemExpress)
93
MedChemExpress urokinase type plasminogen activator upa
In vitro experiments confirming ellagic acid (EA) target on <t>PLAU</t> to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.
Urokinase Type Plasminogen Activator Upa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/urokinase type plasminogen activator upa/product/MedChemExpress
Average 93 stars, based on 1 article reviews
urokinase type plasminogen activator upa - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


UPA inhibits inflammation by silencing IFIT3 in LPS-stimulated macrophages. ( A ) mRNA levels of IFIT3, TNF-α, IL-1β and IL-6 in 100 ng/mL LPS-stimulated macrophages with untreated or treated with 100 nM and 400 nM UPA. ( B ) Protein levels of STAT1, pSTAT1, STAT2, pSTAT2 and IFIT3 among cell-groups. ( C ) Schematic diagram of relation among UPA, IFIT3 and STAT1/2 pathways. Data was presented as mean ± SD from 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Journal of Inflammation Research

Article Title: Downregulation of IFIT3 Relieves the Inflammatory Response in Ulcerative Colitis via Selectively Regulating Macrophage M1 Polarization and the STAT1/2 Signaling Pathway

doi: 10.2147/JIR.S542033

Figure Lengend Snippet: UPA inhibits inflammation by silencing IFIT3 in LPS-stimulated macrophages. ( A ) mRNA levels of IFIT3, TNF-α, IL-1β and IL-6 in 100 ng/mL LPS-stimulated macrophages with untreated or treated with 100 nM and 400 nM UPA. ( B ) Protein levels of STAT1, pSTAT1, STAT2, pSTAT2 and IFIT3 among cell-groups. ( C ) Schematic diagram of relation among UPA, IFIT3 and STAT1/2 pathways. Data was presented as mean ± SD from 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Additionally, M0 THP-1 macrophages were pretreated with 100 nM and 400 nM UPA (#HY-19569, Medchemexpress, New Jersey, USA) for 1 hour prior to stimulation with 100 ng/mL LPS.

Techniques:

In vitro experiments confirming ellagic acid (EA) target on PLAU to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.

Journal: Investigative Ophthalmology & Visual Science

Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling

doi: 10.1167/iovs.67.1.31

Figure Lengend Snippet: In vitro experiments confirming ellagic acid (EA) target on PLAU to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.

Article Snippet: Primary antibodies against PLAU (Proteintech, China; #17968-1-AP), NF-κB p65 (Abcam, UK; #ab32536), phospho-NF-κB p65 (S536; Abcam, UK; #ab76302), GAPDH (ABclonal, China; #AC002), and β-Actin (ABclonal, China; #AC004) were applied overnight at 4°C.

Techniques: In Vitro, Western Blot, Expressing, Irradiation